Karyopharm Therapeutics (KPTI) Non-Current Debt (2024 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Non-Current Debt came in at $94.8 million in Q4 2025, little changed YoY from $94.6 million in Q4 2024, and up 12.99% on a QoQ basis from $83.9 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Non-Current Debt (2024 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 2 years of Non-Current Debt data on file, last reported at $94.8 million in Q4 2025.
- Quarterly Non-Current Debt changed 0.2% year-over-year to $94.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $94.8 million (changed 0.2% YoY) and the FY2025 annual result came in at $94.8 million, changed 0.2% from the prior year.
- Non-Current Debt grew to $94.8 million in Q4 2025, from $83.9 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $95.2 million in Q1 2025 to a low of $83.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 8.96 Bn |
| 10 | Karyopharm Therapeutics | 54.84 Mn | 54.84 Mn | 32.35 Mn | 85.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85.05 Mn |
| Dec 31, 2025 | 94.80 Mn |
| Sep 30, 2025 | 83.90 Mn |
| Jun 30, 2025 | 89.57 Mn |
| Mar 31, 2025 | 95.20 Mn |
| Dec 31, 2024 | 94.60 Mn |
| Sep 30, 2024 | 94.11 Mn |
| Jun 30, 2024 | 93.52 Mn |